Kuca_2009_Basic.Clin.Pharmacol.Toxicol_105_207

Reference

Title : Reactivation of human brain homogenate cholinesterases inhibited by Tabun using newly developed oximes K117 and K127 - Kuca_2009_Basic.Clin.Pharmacol.Toxicol_105_207
Author(s) : Kuca K , Cabal J , Jung YS , Musilek K , Soukup O , Jun D , Pohanka M , Musilova L , Karasova J , Novotny L , Hrabinova M
Ref : Basic Clin Pharmacol Toxicol , 105 :207 , 2009
Abstract : Newly developed acetylcholinesterase reactivators K117 [1,5-bis(4-hydroxyiminomethylpyridinium)-3-oxapentane dichloride] and K127 [(1-(4-hydroxyiminomethylpyridinium)-5-(4-carbamoylpyridinium)-3-oxapentane dibromide)] were tested for their potency to reactivate tabun-inhibited human brain cholinesterases. Pralidoxime and trimedoxime were chosen as standard reference reactivators. Human tissue was used, as that was closer on the real treatment of human beings. As a result, oxime K127 was found as the best tested reactivator according to the constant k(r), characterizing the overall reactivation process. On the contrary, the maximal reactivation ability expressed as percentage of reactivation was the best for trimedoxime. This differences were caused as a result of using the enzyme from different species. Due to this, experiments on human tissue should be conducted after in vitro and in vivo tests on animals to eliminate such important failures of promising oximes.
ESTHER : Kuca_2009_Basic.Clin.Pharmacol.Toxicol_105_207
PubMedSearch : Kuca_2009_Basic.Clin.Pharmacol.Toxicol_105_207
PubMedID: 19473310

Related information

Reactivator K117K127

Citations formats

Kuca K, Cabal J, Jung YS, Musilek K, Soukup O, Jun D, Pohanka M, Musilova L, Karasova J, Novotny L, Hrabinova M (2009)
Reactivation of human brain homogenate cholinesterases inhibited by Tabun using newly developed oximes K117 and K127
Basic Clin Pharmacol Toxicol 105 :207

Kuca K, Cabal J, Jung YS, Musilek K, Soukup O, Jun D, Pohanka M, Musilova L, Karasova J, Novotny L, Hrabinova M (2009)
Basic Clin Pharmacol Toxicol 105 :207